TOP > 外国特許検索 > Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide

Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide NEW

外国特許コード F170009182
整理番号 AF12-05WO
掲載日 2017年9月12日
出願国 アメリカ合衆国
出願番号 201113579529
公報番号 20120322135
公報番号 9365637
出願日 平成23年2月21日(2011.2.21)
公報発行日 平成24年12月20日(2012.12.20)
公報発行日 平成28年6月14日(2016.6.14)
国際出願番号 JP2011053752
国際公開番号 WO2011102517
国際出願日 平成23年2月21日(2011.2.21)
国際公開日 平成23年8月25日(2011.8.25)
優先権データ
  • 特願2010-034998 (2010.2.19) JP
  • 特願2010-035021 (2010.2.19) JP
  • 特願2010-092461 (2010.4.13) JP
  • 2011WO-JP53752 (2011.2.21) WO
発明の名称 (英語) Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide NEW
発明の概要(英語) (US9365637)
The present invention provides: a novel antiviral agent containing a human antibody κ light chain, a novel human abzyme containing a human antibody κ light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody κ light chain of the above; a primer set for effectively obtaining a human antibody κ light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.
特許請求の範囲(英語) [claim1]
1. A human abzyme comprising one of the following (a) through (f): (a) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 24;
(b) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 14, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1;
(c) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 50, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48;
(d) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 35, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33;
(e) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 54, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52; or
(f) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 22, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim2]
2. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, and anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 26,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim3]
3. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, anti influenza virus activity, and cytotoxicity against cancer cells; and
the variable domain consists SEQ ID NO: 14,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1.
[claim4]
4. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity and nucleolytic activity; and
the variable domain consists of SEQ ID NO: 50,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48.
[claim5]
5. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 35,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33.
[claim6]
6. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 54,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52.
[claim7]
7. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity; and
the variable domain consists of SEQ ID NO: 22,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.
[claim8]
8. A method for treating a patient of a rhabdovirus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 30, or 22 to the patient, wherein the administering does not comprise administering a human antibody heavy chain.
[claim9]
9. A method for treating a patient of an influenza virus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 50, 35 or 54 to the patient.
  • 発明者/出願人(英語)
  • UDA TAIZO
  • HIFUMI EMI
  • NISHIZONO AKIRA
  • ARAKAWA MITSUE
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
国際特許分類(IPC)
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close